{"id":"W4387811089","doi":"10.1016/j.annonc.2023.09.2215","title":"1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Loxo Oncology; EMD Serono; Genentech; European Society for Medical Oncology; Eisai; PTC Therapeutics; Rakuten Medical; Seagen; MacroGenics; Pfizer; Symphogen; Moderna; Incyte; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Sun Pharma; Regeneron Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Sanofi; Castle Biosciences; Spectrum Pharmaceuticals; Amgen","keywords":"Medicine; Internal medicine; Adverse effect; Progressive disease; Peripheral edema; Population; Nausea; Gastroenterology; Discontinuation; Response Evaluation Criteria in Solid Tumors; Oncology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002120254,0.0002471798,0.0008151322,0.0002029256,0.0001822906,0.0003880959,0.0002187619,0.0002850645,0.003220482],"category_scores_gemma":[0.0003364145,0.0001426703,0.0004111873,0.0002352367,0.0001508048,0.0001876619,0.0001331989,0.0009921381,0.0004102536],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005147951,"about_ca_system_score_gemma":0.0005998688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002412723,"about_ca_topic_score_gemma":0.006160297,"domain_scores_codex":[0.9998511,0.00003137942,0.00001105253,0.00002339213,0.00003354432,0.00004956342],"domain_scores_gemma":[0.9999142,0.00001392406,0.00001329221,0.000006471374,0.000009079508,0.00004303239],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2177481,0.01034656,0.02428068,0.00150373,0.001539225,0.001408436,0.0001914955,0.002865846,0.2901689,0.0006664498,0.01685012,0.4324303],"study_design_scores_gemma":[0.08958502,0.3430705,0.2847708,0.0003690669,0.004924993,0.007964784,0.000415687,0.01669872,0.1750953,0.0008488445,0.07605594,0.0002002699],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983323,0.01145308,0.000161726,0.0003949505,0.0001541095,0.000094933,0.0004946248,0.0001073217,0.003816193],"genre_scores_gemma":[0.9949944,0.00186496,0.0004000511,0.0002173849,0.000047808,0.00005892987,0.0005237728,0.000008449429,0.001884195],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003220482,"threshold_uncertainty_score":0.01077354,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1335059338046445,"score_gpt":0.4544325932056258,"score_spread":0.3209266594009813,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}